1. Home
  2. INLX vs OTLK Comparison

INLX vs OTLK Comparison

Compare INLX & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellinetics Inc.

INLX

Intellinetics Inc.

HOLD

Current Price

$8.01

Market Cap

36.5M

Sector

Technology

ML Signal

HOLD

Logo Outlook Therapeutics Inc.

OTLK

Outlook Therapeutics Inc.

HOLD

Current Price

$0.49

Market Cap

38.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INLX
OTLK
Founded
1996
2010
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.5M
38.7M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
INLX
OTLK
Price
$8.01
$0.49
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$3.83
AVG Volume (30 Days)
2.2K
1.9M
Earning Date
03-23-2026
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$16,539,674.00
$1,413,535.00
Revenue This Year
N/A
$1,425.11
Revenue Next Year
$15.82
$129.89
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.50
$0.38
52 Week High
$15.72
$3.39

Technical Indicators

Market Signals
Indicator
INLX
OTLK
Relative Strength Index (RSI) 46.09 33.43
Support Level $8.00 $0.38
Resistance Level $8.51 $0.49
Average True Range (ATR) 0.09 0.04
MACD 0.02 0.05
Stochastic Oscillator 25.37 49.85

Price Performance

Historical Comparison
INLX
OTLK

About INLX Intellinetics Inc.

Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Document Management and Document Conversion. The Document Management segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Conversion offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Conversion Segment.

About OTLK Outlook Therapeutics Inc.

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Share on Social Networks: